Singapore, Singapore Oct 31, 2024 (Issuewire.com) - Xylonix, a fast-growing Singapore-based pharmaceutical company specializing in innovative oncology and immunology products, is proud to announce a strategic partnership with Genecast, a pioneering cancer diagnostics company from Korea. This collaboration aims to advance the field of early precision cancer diagnostics and cancer metastasis research, leveraging Genecast's cutting-edge ADPS-PCR technology.
Genecast's Breakthrough in Cancer Diagnostics
Genecast's ADPS (Allele Discriminant Polymerase System) technology represents a significant advancement in cancer diagnostics. This PCR-based ultra-sensitive platform enables the detection of in-blood mutated cfDNA with a frequency as low as 0.01%, making it the most sensitive mutated cancer detection blood test on the market. Genecast offers a comprehensive range of PCR-based oncogene mutation detection kits and cancer panel test kits, targeting high-profile genes such as EGFR, BRAF, KRAS, PIK3CA, and more.
Revolutionizing Cancer Metastasis Research
Xylonix believes that Genecast's ultra-sensitive detection capability of identifying mutated cancer presence from blood will revolutionize and accelerate both clinical and non-clinical cancer metastasis and relapse research by reducing time and cost. Non-clinical cancer metastasis and relapse research in immune-competent test subjects was not accessible to most scientists due to the lengthy time-to-outcome entailing technical, financial, and logistic difficulties. By enabling sensitive quantification of mutated cancer cfDNA, a powerful predictor of distant metastasis[1], this technology promises to accelerate the time of metastasis and relapse research from several months to weeks in non-clinical settings, and from years to months in clinical settings.
A Synergistic Partnership
Under the master cooperation agreement, Xylonix will support Genecast in several key areas. This includes enhancing the visibility and understanding of Genecast’s innovative diagnostics solutions through scientific and medical marketing. Additionally, Xylonix will provide expert guidance to optimize clinical and non-clinical applications of the technology as part of their research advisory. Finally, Xylonix will expand the reach of Genecast products through its established sales networks.
Impact on Global Cancer Research and Treatment
This partnership is poised to make a significant impact on global cancer research and treatment. By making highly sensitive mutation detection accessible through widely available PCR machines, we are democratizing advanced diagnostics and enabling more precise and timely interventions.
"We are thrilled to partner with Genecast, whose innovative ADPS technology aligns perfectly with our mission to combat highly metastatic cancers in IL6-high patients," said Dr. Jinhyuk CHUNG, CEO of Xylonix. "If we can stop metastasis and relapse, cancer will be cured. This collaboration will not only enhance our oncology development success but also empower researchers across the world who share our vision toward that goal.”
"Genecast is excited to work with Xylonix in expanding the use and availability of our ADPS to clinics and cancer researchers around the world," said Byung Chul LEE, CTO & Founder of Genecast. "Together, we can drive significant advancements in cancer detection and treatment."
About Xylonix
Xylonix is a Singapore-incorporated pharmaceutical company dedicated to developing and marketing innovative treatments for disorders driven by post-COVID macrophage, including rhinosinusitis, long COVID, autoimmune disorders, and highly metastatic cancers. Our mission is to provide comprehensive solutions for prevention, symptomatic management, and cures against COVID-endemic disorders, improving patient outcomes worldwide. Our products are currently available in clinics and hospitals across Singapore, with recent expansions into Korea and the Philippines, and with further expansion plans into the USA, China, Japan, and India.
About Genecast
Genecast is a leading cancer diagnostics company based in Korea, known for its ADPS technology that enables ultra-sensitive detection of oncogene mutations with a specified sensitivity of MAF 0.01% in a syngeneic background. Genecast's product portfolio includes a wide range of PCR-based mutation detection kits and cancer panel test kits for early detection and for precision oncology.
For more information, please contact:
Media Officer: Gregory Irving – g.irving@xylonix.io
[1] Huang et al., Ther Adv Med Oncol. 2022. DOI: 10.1177/17588359221106558
Media Contact
Xylonix PTE. LTD. contact@xylonixscience.com 865 Mountbatten Road #06-36 http://xylonix.io
